📊 CVSI Key Takeaways
Investment Thesis
CV Sciences demonstrates severe operational distress with persistent negative profitability across all metrics and deteriorating cash flow generation. The company is consuming cash through operations while maintaining minimal liquidity reserves and substantial debt, creating an unsustainable financial position that threatens long-term viability.
CVSI Strengths
- Reasonable gross margin of 48.5% indicates underlying product economics are viable at the production level
- Current ratio of 1.06x provides minimal short-term liquidity cushion
- Debt-to-equity ratio of 0.83x is moderate relative to total capitalization
CVSI Risks
- Negative operating cash flow of -53.0K combined with -153.0K free cash flow indicates the company is burning through capital reserves and cannot sustain operations from internal cash generation
- Negative net income of -752.0K with net margin of -7.2% and ROE of -48.9% demonstrate the company is not generating shareholder value and is destroying equity
- Quick ratio of 0.21x and cash position of only 381.0K relative to 5.5M in liabilities creates severe liquidity risk; company has less than 2 months of cash at current burn rate
- Revenue flat to declining (-1.9% YoY) while losing money indicates inability to achieve profitable scale or cost control
- No insider buying activity in last 90 days suggests management lacks confidence in near-term prospects
Key Metrics to Watch
- Monthly cash burn rate and runway to insolvency
- Operating cash flow trajectory and path to positive cash generation
- Revenue trend reversal and gross margin sustainability under cost pressure
- Debt refinancing obligations and covenant compliance
- Management changes or strategic pivots to achieve profitability
CVSI Financial Metrics
💡 AI Analyst Insight
CV Sciences, Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
CVSI Profitability Ratios
CVSI vs Healthcare Sector
How CV Sciences, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
CVSI Balance Sheet & Liquidity
CVSI 5-Year Financial Trend
5-Year Trend Summary: CV Sciences, Inc.'s revenue has declined by 70% over the 5-year period, indicating business contraction. The most recent EPS of $0.02 reflects profitable operations.
CVSI Growth Metrics (YoY)
CVSI Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $3.3M | -$109.0K | $0.00 |
| Q2 2025 | $3.6M | -$109.0K | $0.00 |
| Q1 2025 | $3.6M | -$109.0K | $0.00 |
| Q3 2024 | $3.9M | -$447.0K | $0.00 |
| Q2 2024 | $4.0M | -$584.0K | $0.00 |
| Q1 2024 | $4.0M | -$628.0K | $0.00 |
| Q3 2023 | $3.8M | -$447.0K | $0.00 |
| Q2 2023 | $4.0M | -$1.3M | $-0.01 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
CVSI Capital Allocation
CVSI SEC Filings
Access official SEC EDGAR filings for CV Sciences, Inc. (CIK: 0001510964)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CVSI
What is the AI rating for CVSI?
CV Sciences, Inc. (CVSI) has an AI rating of STRONG SELL with 85% confidence, based on fundamental analysis of SEC EDGAR filings.
What are CVSI's key strengths?
Reasonable gross margin of 48.5% indicates underlying product economics are viable at the production level. Current ratio of 1.06x provides minimal short-term liquidity cushion.
What are the risks of investing in CVSI?
Negative operating cash flow of -53.0K combined with -153.0K free cash flow indicates the company is burning through capital reserves and cannot sustain operations from internal cash generation. Negative net income of -752.0K with net margin of -7.2% and ROE of -48.9% demonstrate the company is not generating shareholder value and is destroying equity.
What is CVSI's revenue and growth?
CV Sciences, Inc. reported revenue of $10.5M.
Does CVSI pay dividends?
CV Sciences, Inc. does not currently pay dividends.
Where can I find CVSI SEC filings?
Official SEC filings for CV Sciences, Inc. (CIK: 0001510964) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CVSI's EPS?
CV Sciences, Inc. has a diluted EPS of $0.00.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.